These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29261359)

  • 1. Mapping AcroQoL scores to EQ-5D to obtain utility values for patients with acromegaly.
    Badia X; Trainer P; Biermasz NR; Tiemensma J; Carreño A; Roset M; Forsythe A; Webb SM
    J Med Econ; 2018 Apr; 21(4):382-389. PubMed ID: 29261359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly.
    Wang K; Guo X; Yu S; Gao L; Wang Z; Zhu H; Xing B; Zhang S; Dong D
    Eur J Health Econ; 2021 Dec; 22(9):1381-1391. PubMed ID: 33988760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.
    Davison NJ; Thompson AJ; Turner AJ; Longworth L; McElhone K; Griffiths CEM; Payne K;
    Value Health; 2018 Aug; 21(8):1010-1018. PubMed ID: 30098665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).
    Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM
    Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework.
    Wijeysundera HC; Tomlinson G; Norris CM; Ghali WA; Ko DT; Krahn MD
    Med Decis Making; 2011; 31(3):481-93. PubMed ID: 21127316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
    Thompson NR; Lapin BR; Katzan IL
    Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.
    Versteegh MM; Leunis A; Luime JJ; Boggild M; Uyl-de Groot CA; Stolk EA
    Med Decis Making; 2012; 32(4):554-68. PubMed ID: 22114301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
    Woodcock F; Doble B;
    Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the Beck Depression Inventory to the EQ-5D-3L in Patients with Depressive Disorders.
    Grochtdreis T; Brettschneider C; Hajek A; Schierz K; Hoyer J; Koenig HH
    J Ment Health Policy Econ; 2016 Jun; 19(2):79-89. PubMed ID: 27453455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.